Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (Empire Prevent: Metabolic): A Randomized Controlled Trial
Latest Information Update: 13 Apr 2023
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cerebral ischaemia; Heart failure; Hypertension; Ischaemic heart disorders; Obesity; Renal failure; Stroke
- Focus Therapeutic Use
- Acronyms EMPIRE II Metabolic
- 16 Sep 2021 New trial record